Laborie Unveils Positive Study Results for Optilume® BPH Catheter System
PORTSMOUTH, N.H., May 13, 2024 /PRNewswire/ -- Laborie Medical Technologies Corp. (Laborie), a leading diagnostic and therapeutic medical technology company, announced positive 2-year and 5-year results from studies for its Optilume® BPH Catheter System.
- PORTSMOUTH, N.H., May 13, 2024 /PRNewswire/ -- Laborie Medical Technologies Corp. (Laborie), a leading diagnostic and therapeutic medical technology company, announced positive 2-year and 5-year results from studies for its Optilume® BPH Catheter System.
- The Optilume® BPH Catheter System is a unique minimally invasive surgical therapy (MIST) that combines mechanical dilation using a proprietary double-lobe balloon with concurrent localized delivery of paclitaxel for treating lower urinary tract symptoms (LUTS) secondary to BPH.
- Dr. Kaplan, Director of the Men's Wellness Program at Mount Sinai Health System and Principal investigator for the Optilume® BPH Catheter System PINNACLE trial, presented 2-year data from the PINNACLE study and 5-year data from the EVEREST study.
- "Optilume for BPH is an exciting therapy that offers a safe, effective, and minimally invasive procedure for men suffering from BPH," remarked Dr. Kaplan, "The long-term results from both trials show positive outcomes for men suffering from BPH who undergo this minimally invasive procedure."